Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Third-Quarter 2021 Dividend

Merck Announces Third-Quarter 2021 Dividend

The CHMP recommends approval of Merck's (MRK) anti-PD-1 therapy, Keytruda in combination with chemotherapy for the first-line treatment of esophageal and gastroesophageal junction carcinoma in Europe.

Merck (MRK) Gets CHMP Nod for Keytruda in Esophageal Cancer

Apple

Home Depot

NIKE

Walmart

In this article, we cover our thoughts on five blue chip components in the Dow Jones Industrial Average: Apple, Nike, Merck, Home Depot, and Walmart. Apple and Home Depot are two of our favorites. Apple has a fortress-like balance sheet and generates tremendous free cash flow. Home Depot's omni-channel capabilities are bearing fruit.

5 Blue Chip Stocks In The Dow Jones Industrial Average To Consider

Amgen

Bristol-Myers

General Dynamics

Lockheed Martin

Pfizer

7 High-Quality Dividend Growth Stocks Trading Below Fair Value

Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval for Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) combined with chemotherapy for esophageal cancer. The recommendation is for the first-line treatment in patients with locally advanced unresectable or metastatic carcinoma of the esophagus, or human epidermal growth factor receptor 2-negative gastroesophageal junction adenocarcinoma in adults, whose tumors express PD-L1.

Merck's Keytruda/Chemo Combo Therapy Wins EU Backing For Esophageal Cancer

TOTAL (TOT) signs a 10-year deal with Merck to sell clean energy to the latter. TOTAL is working to scale up renewable energy generation capability by adding new wind and solar assets.

TOTAL (TOT) Signs 10-Year Deal With Merck to Sell Clean Power

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Receives Positive CHMP Opinion for KEYTRUDA in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal Cancer

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as First-Line Treatment for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma

Snowflake

StoneCo

The Oracle of Omaha likely hasn't lost a minute of sleep over these stocks.

3 of Warren Buffett's Biggest Losers of 2021 That Could Still Be Long-Term Winners

Valuations are high for most of the market, but there are still a few places investors can put cash to work. Because of overvaluation during the late 1990s, Merck's stock performance has been poor for the last two decades.

Merck Is A Great Relative Value And A Good Absolute Value

Merck's (MRK) 15-valent pneumococcal conjugate vaccine candidate, V114, demonstrates comparable immunogenicity and safety compared to a lower valency vaccine in infants and children.

Merck's (MRK) Pneumococcal Vaccine Succeeds in Pediatric Trials

Both pharmaceutical companies have new shots designed to protect against more strains of pneumococcal disease.

Merck Battles Pfizer in Lucrative Pediatric Vaccine Market

Merck is one of the largest positions in the pharmaceutical segment in my core portfolio. The company is currently at roughly no P/L in terms of ROIC.

Merck's Valuation Continues To Say 'BUY'

Oncolytics Biotech, Inc.

Oncolytics Biotech Inc (NASDAQ: ONCY) has announced new data from Phase 2 trial evaluating pelareorep in combination with Merck & Co Inc (NYSE: MRK) Keytruda (pembrolizumab) in pancreatic cancer. Data will be presented at the 2021 American Society of Clinical Oncology Annual Meeting.

Oncolytics Pelareorep/Pembrolizumab Combo Therapy Shows Anti-Cancer Activity In Pancreatic Cancer

Micron Technology

NVIDIA

Chemours

Iovance Biotherapeutics

Target

LendingTree

Wendy's

With the trading day almost halfway over, the markets had made a handy recovery on Thursday, bouncing off the lows of last week.

Merck, Micron, Nvidia, Target and More Thursday Afternoon Analyst Calls

Merck & Co Inc's (NYSE: MRK) investigational 15-valent pneumococcal conjugate vaccine, V114, has met its primary immunogenicity and safety endpoints in two Phase 3 pediatric programs. Full results from PNEU-DIRECTION and PNEU-PLAN will be presented at a future scientific congress.

Merck's Next-Gen Pneumococcal Conjugate Vaccine Shows Efficacy In Pediatric Trials

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Positive Topline Results Phase 3 Pediatric Studies for V114, Merck's Investigational 15-valent Pneumococcal Conjugate Vaccine

Merck Announces Positive Topline Results from PNEU-DIRECTION (V114-027) and PNEU-PLAN (V114-024) Phase 3 Pediatric Studies for V114, Merck's Investigational 15-valent Pneumococcal Conjugate Vaccine

Duke Energy

Coca-Cola

Older investors typically rely on income-producing investments to fund their golden years. These prospects offer a healthy balance of dividends, growth, and reliability.

3 Dividend Stocks Perfect for Retirees

Chevron

Wells Fargo

Warren Buffett's Berkshire Hathaway cut back on financial, energy and drug stocks but beefed up his grocery and wireless holdings while adding an insurer.

Warren Buffett's Berkshire Hathaway shakes up investment holdings

WASHINGTON and KENILWORTH, N.J., May 17, 2021 /PRNewswire/ -- Vaccinate Your Family, in collaboration with Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the launch of a new public health campaign called Don't Skip with actress, activist and author Gabrielle Union-Wade to encourage families to schedule their well-visits and stay up to date on all recommended vaccines.

Gabrielle Union-Wade Joins 'Don't Skip' Campaign to Encourage Doctor Well-Visits and Recommended Vaccinations

Teva Pharmaceutical

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Even the Oracle of Omaha is staring at some unrealized losses in his investment portfolio.

3 Stocks Warren Buffett Is Losing Money On Right Now

Physiomics PLC (LON:PYC) jumped 11% to 6.65p in the early afternoon on the back of a further contract with German giant Merck. The consultancy said this contract is additional to the initial tranche of projects with Merck announced in December, with a value of £270,000, to be completed by August.

Physiomics jumps after securing new contract with Merck

Is Merck stock a sell after an independent panel recommended the Food and Drug Administration revoke an approval for blockbuster drug Keytruda as a second option in liver cancer. The post Is Merck Stock A Sell After Panel Suggests Revoking A Keytruda Approval?

Is Merck Stock A Sell After Panel Suggests Revoking A Keytruda Approval?

These two companies should be on your radar.

2 Top Healthcare Stocks for 2021 and Beyond

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival in Patients With Early-Stage Triple-Negative Breast Cancer

Merck Announces Phase 3 KEYNOTE-522 Trial Met Dual Primary Endpoint of Event-Free Survival (EFS) in Patients With High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

MERCK Kommanditgesellschaft auf Aktien (MKGAF) Belén Garijo on Q1 2021 Results - Earnings Call Transcript

News for Merck Stock (MRK)